Montrouge, France, March 8, 2024
DBV Technologies publishes its American “Form 10-K” and its 2023 Universal Registration Document
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq: DBVT), a clinical-stage biopharmaceutical company (the “Company”), today announced that its 2023 Form 10-K has been filed with the Securities and Exchange Commission (“SEC”) in the United States as well as its 2023 universal registration document (“DEU”), with the Autorité des Marchés Financiers (AMF) in France.
The DEU 2023 includes the following information:
The Annual Financial Report;
The Management Report;
The Corporate Governance Report;
The Description of the Share Buyback Program.
The documents can be consulted on the Company’s website at www.dbv-technologies.com in the Investors section. The DEU 2023 is also available on the AMF website (www.amf-france.org), and the “Form 10-K” on the SEC website (www.sec.gov).
A printed version of these documents is also available free of charge at the Company’s headquarters at the following address: 177-181 avenue Pierre Brossolette, 92120 Montrouge.
About DBV Technologies
DBV Technologies is a clinical-stage biopharmaceutical company focused on developing treatment options for food allergies and other immunological conditions with significant unmet medical needs. DBV is currently focused on investigating the use of its proprietary technology platform, Viaskin™, to treat food allergies caused by a hypersensitive immune response and characterized by a range of symptoms ranging in severity from mild to potentially anaphylaxis. deadly. Millions of people live with food allergies, including young children. Using epicutaneous immunotherapy (EPIT™), the Viaskin platform is designed to deliver microgram quantities of a biologically active compound into the immune system through intact skin. EPIT is a new class of non-invasive treatment seeking to modify an individual’s underlying allergy by re-educating the immune system to desensitize to the allergen by taking advantage of the skin’s immune tolerance properties. DBV Technologies is committed to transforming the treatment of people with food allergies. The Company’s food allergy programs include ongoing clinical studies with Viaskin Peanut in young children (ages 1 to 3 years) and children (ages 4 to 7 years) with peanut allergies. DBV Technologies’ global headquarters is located in Montrouge, France, with North American operations based in Basking Ridge, New Jersey. The Company’s ordinary shares are traded on segment B of Euronext Paris (symbol: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing half an ordinary share) are traded on the Nasdaq Global Select Market ( symbol: DBVT) For more information, please visit www.dbvtechnologies.com and contact us on X (formerly Twitter) and LinkedIn.
Contact with investors
Katie Matthews
DBV Technologies
[email protected]
Media Contact
Aurora Krause
DBV Technologies
[email protected]
Attachment